Effect of Ra-223 on Symptomatic Skeletal Events in mCRPC

Review of Lancet Oncology Article: Effect of Ra-223 on Symptomatic Skeletal Events in Patients with mCRPC

Professor Sartor reviews data from a phase 3, double-blind, randomised ALSYMPCA trial and demonstrates improved survival when using radium-223 in treatment of symptomatic CRPC with a few bone metastases.

A. Oliver Sartor, MD
Laborde Professor of Cancer Research
Departments of Medicine and Urology
Medical Director of Tulane Cancer Center
Tulane School of Medicine
New Orleans, Louisiana


Click HERE to read the abstract for Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial